THT Conference 2025 - Outcomes assessing the effect of obesity severity on tirzepatide in patients with obesity-related heart failure with preserved ejection fraction (HFpEF) show that patients on tirzepatide with a greater reduction in BMI and baseline waist-to-height ratio had greater improvements in exercise capacity and KCCQ quality of life scores.

Dr Barry Borlaug (Mayo Clinic and Foundation, Rochester, MN, US) joins us to discuss the findings from the subanlysis of SUMMIT (NCT04847557; Eli Lilly and Company), a randomized, double-blind, placebo-controlled study investigating the dual GIP GLP-1 receptor agonist, tirzepatide in patients with HFpEF and obesity. The subanalysis assessed how changes in baseline BMI and baseline waist-to-height ratio affected the primary endpoints of risk of worsening HF or CV death in patients receiving tirzepatide.

Interview Questions:
1. What is the reasoning behind the SUMMIT trial?
2. What was the specific focus of this subanalysis, and what were the primary findings?
3. What were the secondary findings?
4. How can the findings of the SUMMIT trial be used to identify patients who would benefit most from tirzepatide?
5. What are the next steps?

Recorded remotely from Minnesota, 2025.

Editors: Yazmin Sadik, Jordan Rance
Videographers: David Ben-Harosh, Oliver Miles

Support: This is an independent interview produced by Radcliffe CVRM.